Ricerc@Sapienza

Alzheimer's disease is a devastating neurological illness with a high economic burden. The additional morbidity associated with social issues that arises along with the course of this disorder increases the need for a clear understanding of its etiopathogenesis thus allowing an implementation of novel pharmacological strategies. Despite astrocytes have been long described to actively participate in the regulation of brain circuits, available information is still poor. Even less information is available about their precise role in the pathogenesis of illness.

Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter retrospective study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide extended release. The primary endpoint was change from baseline in HbA1c. Secondary endpoints were changes in fasting plasma glucose, body weight, and systolic blood pressure.